Article Text

Download PDFPDF

Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement
  1. Denis Querleu1,
  2. David Cibula2,
  3. Nicole Concin3,
  4. Anna Fagotti4,
  5. Annamaria Ferrero5,
  6. Christina Fotopoulou6,
  7. Pawel Knapp7,
  8. Dina Kurdiani8,
  9. Jonathan A Ledermann9,
  10. Mansoor Raza Mirza10,
  11. Philppe Morice11,
  12. Jordi Ponce12,
  13. Elzbieta Van der Steen-Banasik13,
  14. Cagatay Taskiran14,
  15. Pauline Wimberger15,
  16. Kamil Zalewski16 and
  17. Cristiana Sessa17
  1. 1 Surgery, Institut Bergonie, Bordeaux, France
  2. 2 Dept of Obstetrics and Gynecology, University of Prague, Prague, Czech Republic
  3. 3 Department of Gynecology and Obstetrics, Innsbruck Medical Univeristy, Innsbruck, Austria
  4. 4 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Rome, Italy
  5. 5 Gynecology and Obstetrics, Academic Department Gynecology and Obstetrics; Mauriziano Hospital; Torino; Italy, Torino, Italy
  6. 6 Gynaecologic Oncology, Imperial College London Faculty of Medicine, London, London, UK
  7. 7 Uniwersytet Medyczny w Bialymstoku, Bialystok, Poland
  8. 8 Tbilisi Cancer Center, Tblisi, Georgia
  9. 9 UCL Cancer Institute (NCRI/MRC), London, UK
  10. 10 Department of Oncology, Rigshospitalet; Copenhagen University Hospital, Copenhagen, Denmark
  11. 11 Institut Gustave-Roussy, Villejuif, Île-de-France, France
  12. 12 University Hospital of Bellvitge (IDIBELL), LHospitalet de Llobregat, Spain
  13. 13 Radiation Oncology, RtG, Arnhem, The Netherlands
  14. 14 Obstetrics and gynecology; Division of Gynecologic Oncology, Gazi University, Ankara, Turkey
  15. 15 Gynecology and Obstetrics, Technische Universitat Dresden Medizinische Fakultat Carl Gustav Carus, Dresden, Pennsylvania, Germany
  16. 16 Gynecologic oncology, Holycross Cancer Center, Kielce, Holycross, Poland
  17. 17 Oncology Institute of Southern Switzerland, Bellinzona, TI, Switzerland
  1. Correspondence to Professor Denis Querleu, Surgery, Institut Bergonie, Bordeaux 33000, France; denis.querleu{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

One randomized study by Ramirez et al and one epidemiological study by Melamed et al1 2 found that the minimal invasive surgery approach for radical hysterectomy for cervical cancer is associated with shorter disease-free and overall survival than open surgery. These findings were confirmed in a recent population-based survey in England.3 In light of the results obtained by these studies the EuropeanSociety of Gynaecological Oncology (ESGO) Scientific Committee and Council herewith issues a statement that the current ESGO recommendation regarding the approach for radical surgery for cervical cancer (“minimal invasive approach is favored”4) is no longer valid. It should be removed and replaced by “open approach is the gold standard”.

ESGO encourages that all minimally invasive surgical procedures for cervical cancer are prospectively recorded, including tumor characteristics and technical details, and performed only in highly specialized centers by appropriately trained surgeons. Patients must be informed about the available prospective and retrospective evidence on survival, complications, and quality of life relating to the two surgical approaches.If minimal access surgery is offered, and accepted by the patient, every effort should be made to avoid spillage of tumor cells in the peritoneal cavity (eg, avoiding crushing lymph nodes, banning vaginal or uterine manipulators, and closing the vaginal cuff in order to avoid any contact between tumor and peritoneal cavity).5 6

As the reasons for the observed overall detrimental effect of minimal access surgery are not clear, and the available research was not designed to identify subgroups potentially amenable to minimal access surgery and/or to investigate the preventive effect of the above mentioned precautions, another trial, incorporating specific precautions and strictly defined quality-assurance criteria, should be developed.



  • Twitter @annafagottimd

  • Contributors This statement has been elaborated via a Delphi process between all members of the ESGO Council.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.